New Frontiers and Emerging Paradigms for Cardiovascular Risk Reduction
in the Setting of Diabetes and ACS

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium:

Internet-based program

Method of Physician Participation Utilized in Learning Process:

There are no fees for participating and receiving CME credit for this activity. During the period December 7, 2011 through December 7, 2013 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) register and complete the evaluation form; and 4) print out your CME certificate.

Estimated Time to Complete Educational Activity:

2.5 hours

Course Overview:

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in antithrombotic interventions for patients with high risk acute coronary syndrome.

Release Date:

December 7, 2011

Expiration Date:

December 7, 2013

Intended Audience:

This program is intended for all cardiovascular-focused clinicians, investigators, program directors, and healthcare providers caring for patients with cardiovascular disease, ACS, and related conditions.

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

This activity is supported by an
educational grant from Genentech

Physician Continuing Education

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The University of Massachusetts Medical School designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity, and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials

Program Faculty and Disclosures:

A. MICHAEL LINCOFF, MD
PROGRAM CHAIRMAN
Vice Chairman, Department of Cardiovascular Medicine
Cleveland Clinic
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Cleveland, OH

Consultant: AstraZeneca, Avanir, Baxter, Bristol-Myers Squibb, Ikaria, Roche, Merck/Schering-Plough
Research Support: Anthera, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Kai Pharmaceuticals, Pfizer, Roche, Novartis, Sanofi-aventis, Merck/Schering-Plough, Scios, Takeda, Johnson & Johnson


JORGE PLUTZKY, MD
Director, The Vascular Disease Prevention Program Cardiovascular Division
Brigham and Women's Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Consultant: Abbott Laboratories; Amylin Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; ChemoCentryz Inc.; Daiichi Sankyo, Inc.; Genentech, Inc.; GlaxoSmithKline; Novo Nordisk; Orexigen Therapeutics, Inc.; Roche; Takeda Pharmaceuticals North America, Inc.; Theratechnologies, Inc.


RICHARD NESTO, MD
Chair, Department of Cardiovascular Medicine
Lahey Clinic Medical Center
Professor of Medicine
Tufts University School of Medicine
Boston, Massachusetts

Consultant: Roche, Genentech, Merck


MICHAEL DAVIDSON, MD
Clinical Professor
The University of Chicago Pritzker School of Medicine
Director of Preventive Cardiology
The University of Chicago Pritzker School of Medicine
Chicago, Illinois

Advisory Board/Consultant: Amgen, Merck, Roche, Sanofi-aventis
Stockholder: Omthera Pharmaceuticals

Program Managers and Web Editor Disclosure:

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives:

Upon completion of this acivity, attendees of this program will:

• Learn about the scientific and clinical research dimensions of ongoing investigations assessing the role of established and emerging agents that may lower cardiovascular (NSTE-ACS and MI), and stroke risk, in the setting of high-risk T2DM, especially after ACS.
  
• Learn about advances in therapeutic strategies based on new mechanisms of action, involving dual peroxisome proliferator-activated receptor-alpha/gamma (PPAR) agonism, on cardiometabolic markers, including lipids, HA1c, glucose levels, and their impact on cardiovascular disease.
  
• Learn about recent advances in our scientific understanding of therapies that appear to possess important vasculopathy-mitigating effects—working through lipid and glycemic regulation as well as other insulin-related mechanisms, including insulin resistance—to reduce the incidence of cardiovascular mortality, non-fatal myocardial infarction and stroke in patients with type 2 diabetes; especially in high-risk patient populations with a history of an ACS event and multiple, associated with risk factors.
  
• Learn about the relationship between T2DM and atherosclerosis and mechanisms that may play a role in mitigating the prothrombotic effects of this disease process.
  
• Learn how emerging therapies might affect signaling and inflammatory signals, including cytokines, inflammation, and insulin resistance, in the vasculopathic cascade that characterizes T2DM and predisposes to macrovascular disease and it cardiovascular complications.
  
• Learn about novel approaches for residual risk reduction and secondary prevention of adverse thromboembolic events in the setting of diabetes after acute coronary syndrome (ACS); and, the need for multi-factorial, multi-parameter risk management of cardiometabolic interfaces that increase CV risk in T2D patients with have ACS.
  

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

• We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
• For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
• We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
• If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
• You should check this privacy policy periodically to see whether we have made any changes.
  
  

Disclaimer:

Copyright © 2011 by CMEducation Resources, LLC All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, or the program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2011 Resources, LLC All rights reserved